Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

詳細情報 詳細情報について

• CRID

  1363670319730794112

• DOI

  10.1016/j.jaad.2017.01.052

• ISSN

  01909622

• Web Site

  https://api.elsevier.com/content/article/PII:S0190962217301469?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S0190962217301469?httpAccept=text/plain

• データソース種別

  • Crossref